Feature	Antigen-Binding Molecule						
	Immunoglobulin (Ig)	T cell receptor (TCR)*	MHC molecules*				
Antigen-binding site	Made up of three CDRs in $V_{\rm H}$ and three CDRs in $V_{\rm L}$ domains	Made up of three CDRs in V_{α} and three CDRs in V_{β} domains	Peptide-binding cleft made of α 1 and α 2 (class I) and α 1 and β 1 (class II) domains				
Nature of antigen that may be bound	Macromolecules (proteins, lipids, polysaccharides) and small chemicals	Peptide-MHC complexes	Peptides				
Nature of antigenic determinants recognized	Linear and conformational determinants of various macromolecules and chemicals	Linear determinants of peptides; only 2 or 3 amino acid residues of a peptide bound to an MHC molecule	Linear determinants of peptides; only some amino acid residues of a peptide				
Affinity of antigen binding	K _d 10 ⁻⁷ -10 ⁻¹¹ M; average affinity of Igs increases during immune response	K _d 10 ⁻⁵ -10 ⁻⁷ M	K _d 10 ⁻⁶ -10 ⁻⁹ M; extremely stable binding				
On-rate and off-rate	Rapid on-rate, variable off-rate	Slow on-rate, slow off-rate	Slow on-rate, very slow off-rate				

CDR, complementarity-determining region; K_d, dissociation constant; MHC, major histocompatibility complex; (only class II molecules depicted); V_H, variable domain of heavy chain Ig; V_L, variable domain of light chain Ig.



Structure of IgG and IgM




Fig. 5-1 A,B



Crystal Structure of Secreted IgG





Fig. 5-1 C



Structure of an Ig Domain





Proteolytic Fragments of IgG (1)




Fig. 5-3A



Proteolytic Fragments of IgG (2)





Fig. 5-3B




Human antibody isotypes

Isotope of Antibody	Subtypes (H Chain)	Serum Concentration (mg/mL)	Serum Half-life (days)	Secreted Form		Functions
IgA	IgA1,2 (α1 or α2)	3.5	6	IgA (dimer) Monomer, dimer, trimer	Cal Ca2 Ca3 J chain	Mucosal immunity
IgD	None (δ)	Trace	3	None		Naive B cell antigen receptor
IgE	None (ε)	0.05	2	lgE Monomer		Defense against helminthic parasites, immediate hypersensitivity
lgG	lgG1-4 (γ1, γ2, γ3, or γ4)	13.5	23	lgG1 Monomer		Opsonization, complement activation, antibody- dependent cell-mediated cytotoxicity, neonatal immunity, feedback inhibition of B cells
IgM	None (μ)	1.5	5	IgM Pentamer	Сµ1 Сµ3 Сµ3 Сµ4 Сµ4 Сµ4 Сµ4 Сµ4 Сµ4 Сµ4 Сµ4 Сµ4 Сµ4	Naive B cell antigen receptor, complement activation




Examples of Ig Superfamily Proteins



Abbas, Lichtman, and Pillai. Cellular and Molecular Immunology, 7th edition. Copyright © 2012 by Saunders, an imprint of Elsevier Inc.



Ig Light Chain Hypervariable Regions





Binding of an Antigen by an Antibody

CDRs Antigen Vн VL CH1 CL




Fig. 5-6 A,B



Antigen and Antibody Binding Surfaces

 Antigen
Residues interacting with antibody

- Ig light chain
 - 🕨 lg heavy chain
- Residues interacting with antigen






Fig. 5-6 C



Flexibility of Antibody Molecules







- Identification of phenotypic markers unique to particular cell types. The basis for the modern classification of lymphocytes and other leukocytes is the recognition of individual cell populations by specific monoclonal antibodies. These antibodies have been used to define clusters of differentiation (CD) markers for various cell types
- Immunodiagnosis. The diagnosis of many infectious and systemic diseases relies on the detection of particular antigens or antibodies in the circulation or in tissues by use of monoclonal antibodies in immunoassays Tumor detection. Tumor-specific monoclonal antibodies are used for detection of tumors by imaging techniques and by staining tissues with labeled antibodies.

 <u>Therapy</u>. Advances in medical research have led to the identification of cells and molecules that are involved in the pathogenesis of many diseases. Monoclonal antibodies, because of their exquisite specificity, provide a means of targeting these cells and molecules. A number of monoclonal antibodies are used therapeutically today. Some examples include antibodies against the cytokine tumor necrosis factor (TNF) used to treat rheumatoid arthritis and other inflammatory diseases, antibodies against CD20 for the treatment of B cell leukemias and for depleting B cells in certain autoimmune disorders, antibodies against the type 2 epidermal growth factor receptor to target breast cancer cells, antibodies against vascular endothelial growth factor (a cytokine that promotes angiogenesis) in patients with colon cancer, and so on

- <u>Tumor detection</u>. Tumor-specific monoclonal antibodies are used for detection of tumors by imaging techniques and by staining tissues with labeled antibodies.
- <u>Functional analysis</u> of cell surface and secreted molecules. In biologic research, monoclonal antibodies that bind to cell surface molecules and either stimulate or inhibit particular cellular functions are invaluable tools for defining the functions of surface molecules, including receptors for antigens. Monoclonal antibodies are also widely used to purify selected cell populations from complex mixtures to facilitate the study of the properties and functions of these cells.

Generation of Monoclonal Antibodies (1)

Creation of Antibody Producing Hybridomas





Fig. 5-9


Generation of Monoclonal Antibodies (2)

Isolation of Hybridoma Clones Producing Anti-X Antibody





Ig Expression During B Cell Maturation



FcRn Prolongs Half-Life of IgG Molecules




Fig. 5-11

Abbas, Lichtman, and Pillai. Cellular and Molecular Immunology, 7th edition. Copyright © 2012 by Saunders, an imprint of Elsevier Inc.



Types of Antigenic Determinants (1)




Fig. 5-12 A,B



Types of Antigenic Determinants (2)

Neoantigenic determinant (created by proteolysis)




Fig. 5-12 C



Valency and Avidity of Antibodies






Fig. 5-13



Antigen-Antibody Complexes





Changes in Ig During Humoral Responses

. .

			Functional significance:		
Original		Changes in	Antigen	Effector	
antibody	а	ntibody structure	recognition	functions	
		Affinity maturation (somatic mutations in variable region)	Increased affinity	No change	
		Change from membrane to secreted form	No change	Change from B cell receptor function to effector function	
	IgA	Isotype switching	No change	Each isotype serves a different set of effector functions	

Fig. 5-15